ResearchMoz

Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies

GBI Research
Published Date » 2013-12-03
No. Of Pages » N/A
   
 GBI Research has released its pharma research, "Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies", which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications....
Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 5
2.1 Ophthalmology Therapeutics in Major Markets is Expected to Reach $6.1 Billion by 2019, with Growth of 7.6% 5
2.2 Moderate Pipeline with Promising Drugs in Late Stages of Development could Drive Market Expectations 7

3 Ophthalmology Therapeutics in Major Markets – Introduction 9
3.1 Dry Eye Syndrome 9
3.1.1 Classification 9
3.1.2 Symptoms 9
3.1.3 Etiology 9
3.1.4 Pathophysiology 10
3.1.5 Diagnosis 11
3.1.6 Epidemiology 12
3.1.7 Prognosis 13
3.1.8 Treatment Options 13
3.2 Glaucoma 14
3.2.1 Classification 14
3.2.2 Symptoms 15
3.2.3 Etiology 15
3.2.4 Pathophysiology 16
3.2.5 Diagnosis 16
3.2.6 Epidemiology 17
3.2.7 Prognosis 18
3.2.8 Treatment Options 18
3.3 GBI Research Report Guidance 19

4 Ophthalmology Therapeutics in Major Markets – Marketed Products (Global) 19
4.1 Dry Eye Syndrome 19
4.2 Glaucoma 20
4.3 Key Marketed Products 21
4.3.1 Restasis 21
4.3.2 Systane 22
4.3.3 Diquas 23
4.3.4 Mucosta 24
4.3.5 Hyalein 25
4.3.6 Lumigan 26
4.3.7 Alphagan/Alphagan P 27
4.3.8 Simbrinza 28

5 Ophthalmology Therapeutics in Major Markets – Pipeline Analysis 28
5.1 Dry Eye Syndrome Pipeline 28
5.1.1 Overall Pipeline 28
5.1.2 Pipeline Analysis by Molecule Type 31
5.1.3 Pipeline Analysis by Mechanism of Action 33
5.2 Glaucoma Pipeline 35
5.2.1 Overall Pipeline 35
5.2.2 Pipeline Analysis by Molecule Type 37
5.2.3 Pipeline Analysis by Mechanism of Action 39
5.3 Promising Drug Candidates in the Pipeline 41
5.3.1 CF-101 41
5.3.2 MIM-D3 41
5.3.3 SAR-1118 41
5.3.4 DE-111 42

6 Ophthalmology Therapeutics in Major Markets – Market Forecast to 2019 42
6.1 Major Markets 42
6.1.1 Treatment Usage Patterns 42
6.1.2 Annual Cost of Therapy 42
6.1.3 Market Size 42
6.2 The US 44
6.2.1 Treatment Usage Patterns 44
6.2.2 Annual Cost of Therapy 44
6.2.3 Market Size 44
6.3 Top Five European Countries 46
6.3.1 Treatment Usage Patterns 46
6.3.2 Annual Cost of Therapy 46
6.3.3 Market Size 46
6.4 Canada 48
6.4.1 Treatment Usage Patterns 48
6.4.2 Annual Cost of Therapy 48
6.4.3 Market Size 48
6.5 Japan 50
6.5.1 Treatment Usage Patterns 50
6.5.2 Annual Cost of Therapy 50
6.5.3 Market Size 50
6.6 Drivers and Barriers 52
6.6.1 Drivers 52
6.6.2 Barriers 52

7 Ophthalmology Therapeutics in Major Markets – Deals and Strategic Consolidations (Global) 53
7.1 Deals Analysis 53
7.2 Major Co-Development Deals 55
7.2.1 NicOx Signs Research Agreement with Pfizer 56
7.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 56
7.2.3 Akorn Enters into Agreement with Azad Pharma 56
7.3 Major Licensing Deals 57
7.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 58
7.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 58
7.3.3 Asterand Enters into Licensing Agreement with Allergan 58

8 Ophthalmology Therapeutics in Major Markets – Appendix 58
8.1 All Pipeline Drugs by Phase 58
8.1.1 Discovery 58
8.1.2 Preclinical 59
8.1.3 IND/CTA-filed 60
8.1.4 Phase I 60
8.1.5 Phase II 62
8.1.6 Phase III 63
8.1.7 Pre-registration 63
8.1.8 Undisclosed 64
8.2 Market Forecasts to 2019 64
8.2.1 Major Markets 64
8.2.2 The US 65
8.2.3 The UK 65
8.2.4 France 66
8.2.5 Germany 67
8.2.6 Italy 67
8.2.7 Spain 68
8.2.8 Canada 69
8.2.9 Japan 69
8.3 Market Definitions 70
8.4 Abbreviations 70
8.5 Sources 72
8.6 Research Methodology 73
8.6.1 Coverage 74
8.6.2 Secondary Research 74
8.6.3 Primary Research 74
8.6.4 Therapeutic Landscape 75
8.6.5 Geographical Landscape 78
8.6.6 Pipeline Analysis 78
8.7 Expert Panel Validation 78
8.8 Contact Us 78
8.9 Disclaimer 78

List of Tables


Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 13
Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 14
Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 18
Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 58
Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 59
Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 60
Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 60
Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 62
Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 63
Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 63
Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 64
Table 12: Ophthalmology Therapeutics Market, Major Markets,, Dry Eye Syndrome, Market Forecast, 2012–2019 64
Table 13: Ophthalmology Therapeutics Market, Major Markets, Glaucoma, Market Forecast, 2012–2019 64
Table 14: Ophthalmology Therapeutics Market, The US, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 15: Ophthalmology Therapeutics Market, The US, Glaucoma, Market Forecast, 2012–2019 65
Table 16: Ophthalmology Therapeutics Market, The UK, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 17: Ophthalmology Therapeutics Market, The UK, Glaucoma, Market Forecast, 2012–2019 66
Table 18: Ophthalmology Therapeutics Market, France, Dry Eye Syndrome, Market Forecast, 2012–2019 66
Table 19: Ophthalmology Therapeutics Market, France, Glaucoma, Market Forecast, 2012–2019 66
Table 20: Ophthalmology Therapeutics Market, Germany, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 21: Ophthalmology Therapeutics Market, Germany, Glaucoma, Market Forecast, 2012–2019 67
Table 22: Ophthalmology Therapeutics Market, Italy, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 23: Ophthalmology Therapeutics Market, Italy, Glaucoma, Market Forecast, 2012–2019 68
Table 24: Ophthalmology Therapeutics Market, Spain, Dry Eye Syndrome, Market Forecast, 2012–2019 68
Table 25: Ophthalmology Therapeutics Market, Spain, Glaucoma, Market Forecast, 2012–2019 68
Table 26: Ophthalmology Therapeutics Market, Canada, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 27: Ophthalmology Therapeutics Market, Canada, Glaucoma, Market Forecast, 2012–2019 69
Table 28: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 29: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012–2019 70

List of Figures


Figure 1: Ophthalmology Therapeutics Market, Major Markets, Market Size (bn), 2012–2019 6
Figure 2: Ophthalmology Therapeutics Market, Global, Pipeline by Stage (%), 2013 8
Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006–2012 21
Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010–2012 23
Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009–2012 24
Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009–2012 25
Figure 7: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006–2012 26
Figure 8: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006–2012 27
Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 29
Figure 10: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 32
Figure 11: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 34
Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 36
Figure 13: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 38
Figure 14: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 40
Figure 15: Ophthalmology Therapeutics Market, Major Markets, Market Size, 2012–2019 43
Figure 16: Ophthalmology Therapeutics Market, The US, Market Size, 2012–2019 45
Figure 17: Ophthalmology Therapeutics Market, Top Five European Countries, Market Size, 2012–2019 47
Figure 18: Ophthalmology Therapeutics Market, Canada, Market Size ($m), 2012–2019 49
Figure 19: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012–2019 51
Figure 20: Ophthalmology Therapeutics Market, Global, Deals, 2006–2013 54
Figure 21: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006–2013 55
Figure 22: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006–2013 57
Figure 23: GBI Research Market Forecasting Model 77

Upcoming Reports:

Exploration & Drilling Security Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast 2014 - 2020
By - Transparency Market Research
The increasing challenges for exploration companies to operate in a challenging environment has led to the development of exploration and drilling security market. Rising production in offshore locations and unconventional sources has led the major exploration companies to invest in drilling and production activities. Many major companies are expanding their present infrastructure in less developed regions, thus security concerns increases with the increasing infrastructure development. To cater the rising security issues and the threat of attacks, many technology developers are heavily...
Carbide Minerals Market - Global Industry Analysis, Size, Share, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Carbide minerals typically comprise types of minerals such as cohenite, haxonite, moissanite and tongbaite. Out of all these types, moissanite is the most important and widely used carbide mineral across the globe. Silicon carbide, which occurs in nature as rarest of rare mineral moissanite, is used in a diverse range of applications such as abrasives and cutting tools, automobile parts, structural materials, electric systems, power electronic devices, LEDs, astronomy, heating elements, thin filament pyrometry, jewelry, nuclear fuel cladding, nuclear fuel particles, catalyst support, steel...
Concrete Superplasticizer Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Superplasticizers are the polymers used as dispersants to improve the flow efficiency of the suspensions by reducing the aggregation of the particles. These are mostly used as admixtures to concretes which improves the strength of the concrete in its’ applications. Concrete superplasticizers are mainly of five types which include modified lignosulfonates, sulfonated melamine formaldehydes, polycarboxylic acids, sulfonated naphthalene formaldehydes and others. The concrete superplasticizers market can be classified based on applications such as high performance, self compacting,...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Healthcare Industry is China is Likely to Boost Green GDP Growth
May 26, 2015  
Leading business analysts are vying on the healthcare industry in China to emerge as the engine of the alleged green GDP growth. Green GDP growth entails environmentally sustainable economic growth. China has been increasingly adopting strategies to ascertain green development of its economic sectors. Healthcare industry of the country shouldn’t be left far behind as well. Speaking about...
E-Learning Course to Facilitate Communication in the Healthcare Industry Launched
May 26, 2015  
We are living in a time when communication is getting highly digitized. Digital technology is evolving at a rapid pace, and now it has expanded its realms to the healthcare industry as well. Recently, Wolters Kluwer from Consortium of Accredited Healthcare Organizations (CAHO) in collaboration with the Baptist Hospital in Bangalore, India released a new e-learning course on communication in...
Healthcare and Pharmaceutical Registers Higher Percent of Inventions than Tech Globally
May 26, 2015  
Thomson Reuters’ analysis on global patents indicates that the life science industry is on the cusp of taking over the tech sector with regards to propelling global innovation.  With a significant increase in the number of patents applied for and granted in 2014, than in any other year of history, experts suggest that humans have never been more proactively inventing....
French Government Forced Supermarkets to Give Unsold Food to Charity
May 26, 2015  
The national assembly of France has vowed a campaign on the wastage of food in the nation by passing a law to stop supermarkets from obliterating unsold food. In spite of destroying food, the super market chains are now enforced to give away the old food to charities or find a way to use these foods somewhere else. The deputy chief of the Socialist Party said that it was shocking to...
Officials from UC Davis and Zhuhai Signed MoU to establish the World Food Center in China
May 26, 2015  
The World Food Center in China is set to be the central office for the co-ordination of R&D and training activities in the field of food safety for many of the Joint Research Centers of China and United States spread across the nation. A unit for the center is being developed in a recently created economic zone in Guangdong province of Zhuhai, a region famous for its economic vitality,...